Accéder au contenu
Merck

Cyclic hypoxia does not alter RAD51 expression or PARP inhibitor cell kill in tumor cells.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2015-04-07)
Ramya Kumareswaran, Naz Chaudary, Karolina Jaluba, Alice Meng, Jenna Sykes, Asm Borhan, Richard P Hill, Robert G Bristow
RÉSUMÉ

Solid tumors contain regions of chronic and cyclic hypoxia. Chronic hypoxia can downregulate RAD51 and sensitize cells to PARP inhibition. Herein, we show that RAD51 expression, cell survival and toxicity to PARP inhibition is not affected under cyclic hypoxic conditions. This suggests that PARP inhibition may be selectively toxic in tumor sub-regions associated with chronic hypoxia.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Iodure de propidium, ≥94.0% (HPLC)
Sigma-Aldrich
Iodure de propidium solution
Sigma-Aldrich
Bicinchoninic acid disodium salt hydrate, ≥98% (HPLC)